Market Summary
USD10.00-0.20
Delayedas of 02 Oct 2023, 03:44 pm-1.96%
TEVA Stock Price
TEVA RSI Chart
TEVA Valuation
TEVA Price/Sales (Trailing)
TEVA Profitability
TEVA Fundamentals
TEVA Revenue
TEVA Earnings
Price Action
52 Week Range
7.0911.45
(Low)(High)
Last 7 days
-1.5%
Last 30 days
5.3%
Last 90 days
35.5%
Trailing 12 Months
30.4%
TEVA Financial Health
TEVA Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for TEVA
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-08-07 | Kalif Eliyahu Sharon | sold | -341,889 | 9.7335 | -35,125 | evp, chief financial officer |
2023-08-04 | Zaks Tal Zvi | acquired | - | - | 15,810 | - |
2023-08-04 | BARER SOL J | acquired | - | - | 28,162 | - |
2023-08-04 | Crane Rosemary A | acquired | - | - | 15,810 | - |
2023-08-04 | Satchi-Fainaro Ronit | acquired | - | - | 15,810 | - |
2023-08-04 | Vergis Janet S. | acquired | - | - | 15,810 | - |
2023-08-04 | LIEBERMAN GERALD M | acquired | - | - | 15,810 | - |
2023-08-04 | Elstein Amir | acquired | - | - | 15,810 | - |
2023-08-04 | Nisen Perry | acquired | - | - | 15,810 | - |
2023-08-04 | Weiss Amir | sold | -19,657 | 9.921 | -1,981 | chief accounting officer |
Which funds bought or sold TEVA recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-26 | BROOKFIELD Corp /ON/ | reduced | -72.04 | -2,948,150 | 920,219 | -% |
2023-09-21 | Baystate Wealth Management LLC | unchanged | - | -528 | 3,012 | -% |
2023-09-21 | Jefferies Group LLC | reduced | -6.16 | 14,688 | 2,087,420 | 0.02% |
2023-09-20 | BARCLAYS PLC | reduced | -41.25 | -7,900,000 | 7,898,000 | -% |
2023-09-12 | Farther Finance Advisors, LLC | added | 80.00 | 917 | 2,643 | -% |
2023-09-07 | ST GERMAIN D J CO INC | new | - | 279 | 279 | -% |
2023-08-24 | Alberta Investment Management Corp | unchanged | - | -157,212 | 896,823 | 0.01% |
2023-08-23 | WOLVERINE TRADING, LLC | added | 21.94 | 63,907 | 1,446,910 | -% |
2023-08-23 | Stonebridge Capital Advisors LLC | unchanged | - | -132 | 753 | -% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -0.16 | -1,560,640 | 8,806,170 | 0.01% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Teva Pharmaceutical Industries
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Jun 09, 2023 | capital research global investors | 0.0% | 0 | SC 13G/A | |
| Feb 13, 2023 | capital research global investors | 10.3% | 114,793,989 | SC 13G/A | |
| Feb 11, 2022 | capital research global investors | 12.0% | 132,350,750 | SC 13G/A | |
| Feb 16, 2021 | capital research global investors | 11.9% | 130,140,247 | SC 13G/A | |
| Feb 03, 2021 | wellington management group llp | 0.03% | 310,793 | SC 13G/A | |
| Feb 14, 2020 | capital research global investors | 11.9% | 130,950,677 | SC 13G/A | |
| Feb 05, 2020 | franklin resources inc | 1.8% | 19,916,016 | SC 13G/A | |
| Jan 28, 2020 | wellington management group llp | 7.43% | 81,123,996 | SC 13G |
Recent SEC filings of Teva Pharmaceutical Industries
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 28, 2023 | 8-K | Current Report | |
| Sep 05, 2023 | 3 | Insider Trading | |
| Sep 05, 2023 | 4 | Insider Trading | |
| Aug 24, 2023 | 8-K | Current Report | |
| Aug 10, 2023 | 3 | Insider Trading | |
| Aug 10, 2023 | 4 | Insider Trading | |
| Aug 09, 2023 | 4 | Insider Trading | |
| Aug 07, 2023 | 4 | Insider Trading | |
| Aug 07, 2023 | 4 | Insider Trading | |
| Aug 07, 2023 | 4 | Insider Trading |
Peers (Alternatives to Teva Pharmaceutical Industries)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
LLY | 483.3B | 29.5B | -1.98% | 63.22% | 74.38 | 16.37 | 1.53% | 14.16% |
JNJ | 404.7B | 97.8B | -4.87% | -4.04% | 31 | 4.14 | 2.29% | -28.92% |
MRK | 272.8B | 58.3B | -6.59% | 20.44% | 17.88 | 4.63 | 2.00% | -81.24% |
PFE | 187.3B | 77.9B | -7.60% | -24.24% | 8.72 | 2.4 | -23.04% | -26.74% |
BMY | 150.1B | 45.2B | -6.96% | -18.45% | 23.72 | 3.25 | -4.15% | 20.34% |
| MID-CAP | ||||||||
RETA | 6.5B | - | 1.99% | 679.20% | -74.1 | 4.1K | -86.94% | 71.24% |
PRGO | 4.3B | 4.6B | -10.37% | -11.13% | -63.85 | 0.93 | 6.60% | 42.04% |
| SMALL-CAP | ||||||||
TLRY | 1.6B | 627.1M | -7.75% | -16.43% | -1.08 | 2.5 | -0.20% | -204.67% |
SUPN | 1.5B | 634.0M | -13.76% | -17.16% | 34.51 | 2.36 | 0.62% | -24.59% |
INVA | 847.3M | 244.3M | 0.39% | 9.53% | 4.3 | 3.47 | -39.50% | -4.99% |
CRON | 762.2M | 109.5M | 6.95% | -31.74% | -5.31 | 6.96 | -2.66% | -32.13% |
ACRS | 484.8M | 31.2M | -8.67% | -53.78% | -4.6 | 15.55 | 407.54% | -26.47% |
CGC | 430.9M | 453.3M | 72.08% | -71.84% | -0.35 | 0.95 | -16.04% | 55.90% |
OCUL | 248.8M | 54.6M | -18.44% | -38.79% | -2.74 | 4.56 | 9.39% | -179.16% |
ENDP | - | 2.2B | - | - | - | - | -22.39% | 63.59% |
Teva Pharmaceutical Industries News
Returns for TEVA
Cumulative Returns on TEVA
-11.2%
10-Year Cumulative Returns
-18.9%
7-Year Cumulative Returns
-13.9%
5-Year Cumulative Returns
4.9%
3-Year Cumulative Returns
Risks for TEVA
What is the probability of a big loss on TEVA?
100%
Probability that Teva Pharmaceutical Industries stock will be more than 20% underwater in next one year
91.2%
Probability that Teva Pharmaceutical Industries stock will be more than 30% underwater in next one year.
37.7%
Probability that Teva Pharmaceutical Industries stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does TEVA drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Teva Pharmaceutical Industries was unfortunately bought at previous high price.
Drawdowns
Financials for Teva Pharmaceutical Industries
Income Statement (Last 12 Months)
| Income Statement (Last 12 Months) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | 0.6% | 15,018,000,000 | 14,926,000,000 | 14,925,000,000 | 15,142,000,000 | 15,434,000,000 | 15,558,000,000 | 15,878,000,000 | 16,233,000,000 | 16,324,000,000 | 16,284,000,000 | 16,659,000,000 | 16,673,000,000 | 16,788,000,000 | 17,095,000,000 | 16,887,000,000 | 16,838,000,000 | 17,130,000,000 | 17,505,000,000 | 18,272,000,000 | 19,251,000,000 | 20,483,000,000 |
| Gross Profit | 0.0% | 6,817,000,000 | 6,815,000,000 | 6,973,000,000 | 7,253,000,000 | 7,378,000,000 | 7,457,000,000 | 7,594,000,000 | 7,593,000,000 | 7,651,000,000 | 7,541,000,000 | 7,726,000,000 | 7,636,000,000 | 7,614,000,000 | 7,744,000,000 | 7,537,000,000 | 7,550,000,000 | 7,697,000,000 | 7,837,000,000 | 8,296,000,000 | 8,769,000,000 | 9,391,000,000 |
| S&GA Expenses | 0.4% | 2,237,000,000 | 2,228,000,000 | 2,265,000,000 | 2,348,000,000 | 2,406,000,000 | 2,427,000,000 | 2,429,000,000 | 2,480,000,000 | 2,488,000,000 | 2,470,000,000 | 2,498,000,000 | 2,521,000,000 | 2,511,000,000 | 2,580,000,000 | 2,614,000,000 | 2,706,000,000 | 2,810,000,000 | 2,826,000,000 | 2,916,000,000 | 2,769,000,000 | 2,913,000,000 |
| R&D Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 114,000,000 | 54,000,000 | 229,000,000 |
| EBITDA | 100.0% | - | -116,000,000 | -809,000,000 | - | -594,000,000 | 1,712,000,000 | 2,879,000,000 | - | - | -1,794,000,000 | -1,948,000,000 | -2,182,000,000 | 2,017,000,000 | 1,286,000,000 | 1,279,000,000 | -2,005,000,000 | -1,865,000,000 | -1,236,000,000 | 166,000,000 | -9,554,000,000 | -9,169,000,000 |
| EBITDA Margin | 100.0% | - | -0.01 | -0.05 | - | -0.04 | 0.11 | 0.18 | - | - | -0.11 | -0.12 | -0.13 | 0.12 | 0.07 | 0.07 | -0.12 | -0.11 | -0.07 | 0.01 | -0.49 | -0.44 |
| Interest Expenses | - | - | - | 948,000,000 | - | - | - | 913,000,000 | - | - | - | 846,000,000 | - | - | - | 840,000,000 | - | - | - | 815,000,000 | - | - |
| Earnings Before Taxes | 10.5% | -2,107,000,000 | -2,353,000,000 | -3,065,000,000 | -2,140,000,000 | -1,924,000,000 | -456,000,000 | 658,000,000 | 971,000,000 | -3,870,000,000 | -4,229,000,000 | -4,406,000,000 | -4,582,000,000 | -415,000,000 | -1,214,000,000 | -1,265,000,000 | -4,613,000,000 | -4,534,000,000 | -3,934,000,000 | -2,596,000,000 | -12,417,000,000 | -12,085,000,000 |
| EBT Margin | 100.0% | - | -0.16 | -0.21 | -0.14 | -0.12 | -0.03 | 0.04 | 0.06 | -0.24 | -0.26 | -0.26 | -0.27 | -0.02 | -0.07 | -0.07 | -0.27 | -0.26 | -0.22 | -0.14 | -0.63 | -0.58 |
| Net Income | -39.4% | -2,233,000,000 | -1,602,000,000 | -2,353,000,000 | -1,290,000,000 | -1,054,000,000 | -615,000,000 | 417,000,000 | 726,000,000 | -3,915,000,000 | -3,982,000,000 | -3,990,000,000 | -4,030,000,000 | 5,000,000 | -824,000,000 | -998,000,000 | -3,994,000,000 | -3,888,000,000 | -3,375,000,000 | -2,150,000,000 | -10,799,000,000 | -9,996,000,000 |
| Net Income Margin | 100.0% | - | -0.11 | -0.16 | -0.09 | -0.07 | -0.04 | 0.03 | 0.04 | -0.24 | -0.24 | -0.24 | -0.24 | 0.00 | -0.05 | -0.06 | -0.23 | -0.22 | -0.19 | -0.11 | -0.55 | -0.48 |
| Free Cashflow | -100.0% | - | 964,000,000 | 1,042,000,000 | 514,000,000 | 476,000,000 | 585,000,000 | 236,000,000 | 88,000,000 | -131,000,000 | -94,000,000 | 638,000,000 | 902,000,000 | 894,000,000 | 413,000,000 | 223,000,000 | -42,000,000 | 84,000,000 | 449,000,000 | 1,795,000,000 | 2,233,000,000 | 2,534,000,000 |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | -0.8% | 43,095 | 43,456 | 44,006 | 44,252 | 45,932 | 47,059 | 47,666 | 47,851 | 49,195 | 49,004 | 50,640 | 49,737 | 54,991 | 55,330 | 57,470 | 57,246 | 59,424 | 59,854 | 60,683 | 65,061 | 67,030 |
| Current Assets | 5.1% | 12,088 | 11,501 | 12,051 | 11,453 | 12,164 | 12,451 | 12,573 | 12,154 | 12,822 | 12,401 | 13,005 | 12,160 | 12,781 | 12,884 | 13,464 | 12,542 | 13,805 | 13,431 | 13,794 | 13,881 | 14,711 |
| Cash Equivalents | 22.7% | 2,669 | 2,176 | 2,801 | 2,225 | 2,058 | 2,250 | 2,198 | 2,045 | 2,436 | 1,743 | 2,177 | 1,827 | 2,402 | 1,804 | 1,975 | 1,241 | 2,165 | 1,973 | 1,782 | 1,875 | 1,861 |
| Inventory | -0.2% | 4,109 | 4,118 | 3,833 | 3,859 | 4,049 | 4,012 | 3,818 | 4,167 | 4,362 | 4,406 | 4,403 | 4,516 | 4,361 | 4,290 | 4,422 | 4,636 | 4,850 | 4,782 | 4,731 | 4,866 | 4,971 |
| Net PPE | -0.7% | 5,712 | 5,751 | 5,739 | 5,568 | 5,740 | 5,932 | 5,982 | 6,040 | 6,127 | 6,112 | 6,296 | 6,152 | 6,122 | 6,221 | 6,436 | 6,643 | 6,732 | 6,785 | 6,868 | 7,101 | 7,213 |
| Goodwill | -3.8% | 17,118 | 17,799 | 17,633 | 18,433 | 18,837 | 19,986 | 20,040 | 20,179 | 20,421 | 20,302 | 20,624 | 20,228 | 24,616 | 24,490 | 24,846 | 24,657 | 24,913 | 24,822 | 24,917 | 27,585 | 27,648 |
| Liabilities | 1.6% | 35,387 | 34,844 | 35,315 | 34,734 | 36,103 | 36,799 | 36,422 | 36,400 | 37,884 | 38,029 | 39,579 | 39,145 | 40,167 | 40,742 | 42,407 | 42,322 | 44,173 | 44,033 | 44,889 | 45,927 | 47,662 |
| Current Liabilities | 13.8% | 11,843 | 10,411 | 11,469 | 11,534 | 10,996 | 11,613 | 11,027 | 11,825 | 12,691 | 12,089 | 13,164 | 12,103 | 11,751 | 12,322 | 13,674 | 14,107 | 14,452 | 14,028 | 14,322 | 14,830 | 14,215 |
| Shareholder's Equity | -18.1% | 7,052 | 8,612 | 7,897 | 8,767 | 9,828 | 10,260 | 11,244 | 11,451 | 11,311 | 10,975 | 11,061 | 10,592 | 14,824 | 14,588 | 15,063 | 14,925 | 15,251 | 15,821 | 15,794 | 19,134 | 19,368 |
| Retained Earnings | -6.6% | -13,950 | -13,086 | -12,882 | -11,660 | -11,716 | -11,484 | -10,529 | -10,370 | -10,662 | -10,869 | -10,946 | -11,096 | -6,747 | -6,887 | -6,956 | -7,066 | -6,752 | -6,063 | -5,958 | -3,072 | -2,864 |
| Additional Paid-In Capital | 0.1% | 27,748 | 27,719 | 27,688 | 27,652 | 27,625 | 27,587 | 27,561 | 27,529 | 27,503 | 27,474 | 27,443 | 27,403 | 27,374 | 27,342 | 27,312 | 27,293 | 27,258 | 27,234 | 27,210 | 23,404 | 23,426 |
| Shares Outstanding | 0.4% | 1,120 | 1,115 | - | 1,111 | 1,110 | 1,107 | - | 1,103 | 1,103 | 1,099 | - | 1,096 | 1,096 | 1,093 | - | 1,092 | 1,092 | 1,090 | - | 1,018 | 1,018 |
| Minority Interest | -12.6% | 656 | 751 | 794 | 751 | 791 | 916 | 966 | 984 | 987 | 975 | 1,035 | 999 | 972 | 1,057 | 1,091 | 1,134 | 1,128 | 1,089 | 1,087 | 1,404 | 1,430 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | 13.5% | 1,695 | 1,494 | 1,590 | 1,073 | 1,059 | 1,154 | 798 | 673 | 451 | 506 | 1,216 | 1,423 | 1,441 | 941 | 748 | 577 | 673 | 1,062 | 2,446 | 2,938 | 3,312 |
| Share Based Compensation | -6.8% | 123 | 132 | 124 | 121 | 122 | 112 | 119 | 124 | 127 | 130 | 129 | 111 | 117 | 115 | 119 | 132 | 142 | 159 | 155 | 149 | 135 |
| Cashflow From Investing | 18.2% | 798 | 675 | 656 | 733 | 874 | 1,176 | 1,523 | 1,418 | 1,287 | 1,119 | 863 | 1,152 | 1,219 | 1,335 | 1,355 | 999 | 1,122 | 1,099 | 1,866 | 3,704 | 3,461 |
| Cashflow From Financing | 12.9% | -1,912 | -2,195 | -1,487 | -1,277 | -2,014 | -1,677 | -2,172 | -1,796 | -1,676 | -1,678 | -1,885 | -2,001 | -2,405 | -2,437 | -1,926 | -2,184 | -1,428 | -1,449 | -3,351 | -5,358 | -5,478 |
| Dividend Payments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 12.00 | 99.00 | 222 |
TEVA Income Statement
2023-06-30Consolidated Statements of Income (Loss) - USD ($) shares in Millions, $ in Millions | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Net revenues | $ 3,878 | $ 3,786 | $ 7,539 | $ 7,447 |
| Cost of sales | 2,082 | 1,992 | 4,161 | 3,913 |
| Gross profit | 1,796 | 1,794 | 3,378 | 3,534 |
| Research and development expenses | 240 | 228 | 473 | 453 |
| Selling and marketing expenses | 603 | 594 | 1,149 | 1,178 |
| General and administrative expenses | 307 | 313 | 602 | 609 |
| Intangible assets impairments | 63 | 51 | 241 | 199 |
| Goodwill impairment | 700 | 745 | 700 | 745 |
| Other assets impairments, restructuring and other items | 100 | 118 | 195 | 246 |
| Legal settlements and loss contingencies | 462 | 729 | 695 | 1,854 |
| Other income | (33) | (34) | (34) | (87) |
| Operating income (loss) | (646) | (949) | (644) | (1,662) |
| Financial expenses, net | 268 | 211 | 528 | 468 |
| Income (loss) before income taxes | (914) | (1,160) | (1,172) | (2,131) |
| Income taxes (benefit) | (16) | (900) | (35) | (899) |
| Share in (profits) losses of associated companies, net | (1) | 0 | (1) | (21) |
| Net income (loss) | (898) | (259) | (1,136) | (1,211) |
| Net income (loss) attributable to non-controlling interests | (35) | (27) | (68) | (24) |
| Net income (loss) attributable to Teva | $ (863) | $ (232) | $ (1,068) | $ (1,187) |
| Earnings (loss) per share attributable to ordinary shareholders: | ||||
| Basic | $ (0.77) | $ (0.21) | $ (0.96) | $ (1.07) |
| Diluted | $ (0.77) | $ (0.21) | $ (0.96) | $ (1.07) |
| Weighted average number of shares (in millions): | ||||
| Basic | 1,120 | 1,110 | 1,118 | 1,109 |
| Diluted | 1,120 | 1,110 | 1,118 | 1,109 |
TEVA Balance Sheet
2023-06-30Consolidated Balance Sheets - USD ($) $ in Millions | Jun. 30, 2023 | Dec. 31, 2022 | ||
|---|---|---|---|---|
| Current assets: | ||||
| Cash and cash equivalents | $ 2,669 | $ 2,801 | ||
| Accounts receivables, net of allowance for credit losses of $87 million and $91 million as of June 30, 2023 and December 31, 2022 | 3,539 | 3,696 | ||
| Inventories | 4,109 | 3,833 | ||
| Prepaid expenses | 1,228 | 1,162 | ||
| Other current assets | 486 | 549 | ||
| Assets held for sale | 56 | 10 | ||
| Total current assets | 12,088 | 12,051 | ||
| Deferred income taxes | 1,578 | 1,453 | ||
| Other non-current assets | 443 | 441 | ||
| Property, plant and equipment, net | 5,712 | 5,739 | ||
| Operating lease right-of-use assets, net | 418 | 419 | ||
| Identifiable intangible assets, net | 5,738 | 6,270 | ||
| Goodwill | [1] | 17,118 | 17,633 | |
| Total assets | 43,095 | 44,006 | ||
| Current liabilities: | ||||
| Short-term debt | 1,980 | 2,109 | ||
| Sales reserves and allowances | 3,433 | 3,750 | ||
| Accounts payables | 2,508 | 1,887 | ||
| Employee-related obligations | 451 | 566 | ||
| Accrued expenses | 2,498 | 2,151 | ||
| Other current liabilities | 973 | 1,005 | ||
| Total current liabilities | 11,843 | 11,469 | ||
| Long-term liabilities: | ||||
| Deferred income taxes | 534 | 548 | ||
| Other taxes and long-term liabilities | 3,973 | 3,847 | ||
| Senior notes and loans | 18,698 | 19,103 | ||
| Operating lease liabilities | 338 | 349 | ||
| Total long-term liabilities | 23,543 | 23,846 | ||
| Commitments and contingencies, see note 10 | ||||
| Total liabilities | 35,387 | 35,315 | ||
| Teva shareholders' equity: | ||||
| Ordinary shares of NIS 0.10 par value per share; June 30, 2023 and December 31, 2022: authorized 2,495 million shares; issued 1,227 million shares and 1,217 million shares, respectively. | 57 | 57 | ||
| Additional paid-in capital | 27,748 | 27,688 | ||
| Accumulated deficit | (13,950) | (12,882) | ||
| Accumulated other comprehensive loss | (2,677) | (2,838) | ||
| Treasury shares as of June 30, 2023 and December 31, 2022: 106 million ordinary shares | (4,128) | (4,128) | ||
| Stockholders' equity attributable to Teva shareholders | 7,052 | 7,897 | ||
| Non-controlling interests | 656 | 794 | ||
| Total equity | 7,708 | 8,691 | ||
| Total liabilities and equity | $ 43,095 | $ 44,006 | ||
| ||||
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.